IMU Biosciences and UK Biobank will profile 80,000 blood samples using technologies from Waters and Ultima Genomics.
"Mi insegni?", "Mi fai vedere come si fa?”, “Lo facciamo insieme?". Quante volte un nonno o una nonna si sentono rivolgere queste domande. È il bello di essere dei tutorial in carne e ossa con ...
We seem to have reached peak “get off my lawn” culture, with men having temper tantrums all over the damn place. Whether they’re typing shrill all-caps messages, foaming at the mouth with road rage or ...
--- In a large China real-world study of 281 heavily pretreated, predominantly high-risk patients with relapsed/refractory plasma cell neoplasms, FUCASO achieved a 95.9% objective response rate, a ...
— Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting ...
— Poster presentation selected for the poster discussion session (Abstract No.: PA-200): in a first-in-human study in 9 heavily pretreated, high-risk patients with relapsed/refractory multiple myeloma ...
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of Action Biomarker Data from First ...
MRD negativity at 10⁻⁶ independently correlated with prolonged PFS in GEM2014MAIN, enabling treatment discontinuation after 2 years for sustained MRD-negative patients with excellent 7-year landmark ...
Mezigdomide plus elranatamab achieved a 100% ORR and a 92.3% CR or better rate in evaluable anti-BCMA–naive R/R MM, with MRD negativity in 87.5% of assess patients with stringent CRs. Toxicity with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results